https://staging.altals.com/blog/2017/09/06/peptomyc-s-l-secures-4-2-million-euros-in-series-a-led-by-alta-life-sciences/2019-09-11T18:02:52+02:00https://staging.altals.com/blog/2018/05/17/alta-life-sciences-is-leading-a-4m-e-round-to-finance-the-clinical-development-of-the-bionuress-neuroprotector-bn201/2019-08-14T11:04:54+02:00https://staging.altals.com/blog/2019/06/28/alta-life-sciences-participates-in-sanifits-552me-series-d-round-led-by-caixa-capital-risc/2019-08-14T11:04:44+02:00https://staging.altals.com/blog/2018/09/13/mediktor-closes-a-funding-round-of-3-million-euros-with-the-aim-of-entering-the-us-market/2019-09-11T18:02:25+02:00https://staging.altals.com/blog/2019/09/26/8171/2019-09-29T16:42:10+02:00https://staging.altals.com/blog/2019/10/31/sanifit-announces-that-the-phase-2b-calipso-trial-of-snf472-met-its-primary-endpoint-in-slowing-the-progression-of-cardiovascular-calcification-in-patients-on-hemodialysis/2019-10-31T16:18:40+02:00https://staging.altals.com/blog/2020/05/27/accure-therapeutics-launches-with-e7-6m-series-a-round/2020-05-27T12:19:45+02:00https://staging.altals.com/blog/2020/06/01/sanifit-enhances-leadership-team-with-new-executive-appointments/2020-06-01T12:43:06+02:00https://staging.altals.com/blog/2020/06/11/sabadell-asabys-y-alta-life-sciences-apuestan-por-el-grafeno-en-el-ambito-de-las-terapias-electronicas-neuronales-y-colideran-la-inversion-en-inbrain-neuroelectronics/2020-06-11T10:44:02+02:00https://staging.altals.com/blog/2020/06/16/alta-life-sciences-invests-in-ona-therapeutics-e30m-series-a/2020-06-16T09:16:51+02:00https://staging.altals.com/blog/2020/07/07/deepull-closes-series-a-financing-led-by-alta-life-sciences-and-kurma-partners-to-improve-early-diagnosis-of-sepsis/2020-07-07T09:01:03+02:00https://staging.altals.com/blog/2020/12/16/peptomyc-announces-a-new-equity-financing-round-of-11-4me/2020-12-16T00:53:30+02:00https://staging.altals.com/blog/2021/01/11/sanifit-subgroup-analyses-from-sanifits-calipso-phase-2b-clinical-study-published-in-kidney-international-reports/2021-01-11T12:37:05+02:00https://staging.altals.com/blog/2021/01/11/sanifit-to-participate-in-the-2021-icr-conference/2021-01-11T12:38:05+02:00https://staging.altals.com/blog/2021/01/11/peptomyc-steps-forward-as-a-clinical-stage-biotech-company/2021-01-11T12:37:49+02:00https://staging.altals.com/blog/2021/01/11/peptomyc-board-of-directors-appoints-giacomo-di-nepi-as-chairman-of-the-board/2021-01-11T12:38:17+02:00https://staging.altals.com/blog/2021/01/11/binx-health-receives-eua-authorizing-at-home-covid-19-sample-collection-by-universities-and-employers/2021-01-11T12:37:19+02:00https://staging.altals.com/blog/2021/01/12/accure-therapeutics-strengthens-scientific-advisory-board-by-appointing-top-class-scientists/2021-01-12T13:29:39+02:00https://staging.altals.com/blog/2021/01/21/alta-life-sciences-leads-an-oversubscribed-investment-round-into-inbiomotion-to-launch-its-diagnostic-product-in-breast-cancer/2021-01-21T00:40:17+02:00https://staging.altals.com/blog/2021/01/26/accure-therapeutics-appoints-dr-rossella-medori-as-chief-medical-officer/2021-01-26T17:10:45+02:00https://staging.altals.com/blog/2021/02/09/alta-life-sciences-engorda-en-el-ano-del-covid-19-el-fondo-de-altamar-invierte-veinte-millones/2021-02-09T10:37:35+02:00https://staging.altals.com/blog/2021/02/10/accure-therapeutics-webinars-on-neuroprotection-for-brain-diseases-program/2021-02-10T12:19:55+02:00https://staging.altals.com/blog/2021/02/11/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/2021-02-11T10:48:23+02:00https://staging.altals.com/blog/2021/02/12/accure-therapeutics-publishes-pivotal-preclinical-efficacy-study-in-epilepsy/2021-03-01T14:15:02+02:00https://staging.altals.com/blog/2021/02/21/binx-health-enters-into-distribution-agreement-for-national-launch-of-the-fda-cleared-binx-io/2021-03-03T11:38:06+02:00https://staging.altals.com/blog/2021/02/25/alta-life-sciences-participa-en-el-grupo-de-trabajo-de-asebio-para-impulsar-el-sector-biotech/2021-02-25T15:38:35+02:00https://staging.altals.com/blog/2021/03/02/accure-therapeutics-enrols-first-patient-in-phase-ii-clinical-trial-on-acute-optic-neuritis-with-lead-candidate-act-01/2021-03-02T12:48:40+02:00https://staging.altals.com/blog/2021/03/05/ona-therapeutics-appoints-mark-throsby-to-its-board-of-directors/2021-03-05T09:40:53+02:00https://staging.altals.com/blog/2021/03/11/veteran-healthcare-leader-david-p-king-joins-binx-health-board-of-directors/2021-03-11T11:57:21+02:00https://staging.altals.com/blog/2021/03/18/green-light-by-the-aemps-to-start-clinical-trials-with-omo-103/2021-03-18T10:03:12+02:00https://staging.altals.com/blog/2021/03/18/binx-health-collaborates-with-amazon-business-for-delivery-of-covid-19-sample-collection-kits-to-u-s-businesses-schools-and-governments/2021-03-18T10:07:53+02:00https://staging.altals.com/blog/2021/03/26/inbrain-neuroelectronics-raises-over-e14m-series-a-led-by-alta-life-sciences-asabys-partners-and-cdti-to-develop-intelligent-graphene-based-neuroelectronic-therapies-for-brain-related-disorders/2021-03-26T08:54:43+02:00https://staging.altals.com/blog/2021/03/30/fda-allows-for-first-point-of-care-chlamydia-and-gonorrhea-test-to-be-used-in-more-near-patient-care-settings/2021-03-30T21:05:57+02:00https://staging.altals.com/blog/2021/05/06/peptomyc-sl-announces-treatment-of-first-patient-with-its-lead-compound-omo-103-in-a-phase-i-ii-clinical-trial/2021-05-06T09:30:15+02:00https://staging.altals.com/blog/2021/05/18/binx-health-submits-request-for-emergency-use-authorization-for-first-crispr-based-point-of-care-test-for-covid-19/2021-05-18T14:17:49+02:00https://staging.altals.com/blog/2021/05/28/binx-health-raises-104-million-in-series-e-financing/2021-05-28T00:09:11+02:00https://staging.altals.com/blog/2021/07/23/spanish-startups-and-scaleups-to-watch/2021-07-23T20:01:27+02:00https://staging.altals.com/blog/2021/09/10/graphene-flagship-spin-off-inbrain-signs-collaboration-with-merck-to-develop-next-generation-bioelectronics/2021-09-10T10:15:26+02:00https://staging.altals.com/blog/2021/09/30/inbiomotions-maf-test-selects-breast-cancer-patients-benefitting-from-adjuvant-clodronate-significantly-improving-their-overall-survival/2021-09-30T11:09:35+02:00https://staging.altals.com/blog/2021/10/04/deepull-appoints-richard-ivey-to-its-board-of-directors/2021-10-04T09:47:40+02:00https://staging.altals.com/blog/2021/10/04/mediktor-raises-e11m-round-for-its-ai-triage-and-pre-diagnosis-medical-assistant/2021-10-04T18:30:06+02:00https://staging.altals.com/blog/2021/10/21/ona-therapeutics-strengthens-scientific-leadership-team/2021-10-21T09:33:20+02:00https://staging.altals.com/blog/2021/11/22/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/2021-11-22T09:41:47+02:00https://staging.altals.com/blog/2021/11/22/vifor-pharma-adquirira-sanifit-para-reforzar-su-cartera-de-productos-en-fase-avanzada-en-nefrologia/2021-11-22T09:44:19+02:00https://staging.altals.com/blog/2021/12/02/ona-therapeutics-appoints-dr-michel-detheux-as-independent-chair-to-board-of-directors/2021-11-30T12:19:46+02:00https://staging.altals.com/blog/2021/12/10/binx-health-and-student-health-insurer-wellfleet-expand-agreement-in-college-health-for-in-dorm-and-at-home-access-to-testing-for-sexually-transmitted-infections-stis/2021-12-10T10:48:39+02:00https://staging.altals.com/blog/2021/12/15/binx-health-selected-as-a-top-digital-health-startup-that-is-transforming-the-future-of-healthcare-named-to-the-2021-cb-insights-digital-health-150-list/2021-12-15T11:31:35+02:00https://staging.altals.com/blog/2022/01/18/peptomyc-logra-86-millones-de-sus-socios-y-busca-mas-inversores/2022-01-18T11:01:43+02:00https://staging.altals.com/blog/2022/03/02/oculis-strengthens-leading-ophthalmology-pipeline-by-inlicensing-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2022-03-02T14:30:22+02:00https://staging.altals.com/blog/2022/07/14/study-shows-that-selection-of-breast-cancer-patients-for-adjuvant-bisphosphonate-therapy-based-on-inbiomotions-maftest-reduces-the-risk-of-death-in-comparison-with-current-clinical-guid/2022-07-13T18:10:32+02:00https://staging.altals.com/blog/2022/10/20/deepull-raises-e13m-series-b-financing-to-progress-early-sepsis-recognition-platform/2022-10-20T12:09:19+02:00https://staging.altals.com/blog/2022/11/03/amid-national-surge-in-sexually-transmitted-infections-binx-health-announces-launch-of-reagent-rental-program-for-decentralized-rapid-point-of-care-testing-platform-for-chlamydia-and-gonorrhea/2022-11-03T10:32:01+02:00https://staging.altals.com/blog/2023/03/14/acp-aliath-bioventures-ii-fcr-fund-has-been-registered/2023-03-14T15:04:25+02:00https://staging.altals.com/blog/2023/09/19/aliath-bioventures-appoints-dr-philippe-monteyne-and-announces-additional-hires-to-further-strengthen-its-life-sciences-impact-business/2023-09-19T11:09:53+02:00https://staging.altals.com/blog/2023/09/20/inbrain-neuroelectronics-wins-fda-breakthrough-nod-for-intelligent-network-modulation-system/2023-09-20T10:48:54+02:00https://staging.altals.com/blog/2023/11/28/binx-health-expands-nationwide-distribution-of-the-binx-io-molecular-point-of-care-platform/2024-09-04T12:17:51+02:00https://staging.altals.com/blog/2024/02/14/nature-medicine-peptomycs-first-myc-inhibitor-omo-103-demonstrates-safety-and-anti-tumor-activity-in-a-phase-i-clinical-trial/2024-02-14T12:12:05+02:00https://staging.altals.com/blog/2024/02/14/binx-health-enters-into-national-distribution-agreement-with-cardinal-health-to-increase-access-to-the-clia-waived-fda-cleared-binx-io/2024-09-04T12:15:19+02:00https://staging.altals.com/blog/2024/02/26/spanish-biotech-peptomyc-advances-myc-inhibitorin-pancreatic-cancer-after-positive-early-data/2024-02-26T13:38:26+02:00https://staging.altals.com/blog/2024/03/22/peptomyc-appoints-selwyn-ho-to-its-board-of-directors/2024-03-22T12:17:21+02:00https://staging.altals.com/blog/2024/04/11/why-your-company-needs-an-ai-assistant-patient-engagement-from-first-contact/2024-09-04T12:16:32+02:00https://staging.altals.com/blog/2024/04/29/deepull-unveils-1-hour-direct-from-blood-multiplex-pcr-test-for-95-of-sepsis-causing-pathogens-at-escmid-2024/2024-09-04T12:14:36+02:00https://staging.altals.com/blog/2024/05/16/peptomyc-has-been-granted-40-000-e-within-the-activa-startups/2024-05-16T10:36:41+02:00https://staging.altals.com/blog/2024/05/16/accure-therapeutics-awarded-e1-million-from-spanish-government-to-evaluate-act-03-for-post-traumatic-epilepsy/2024-05-16T10:34:09+02:00https://staging.altals.com/blog/2024/05/16/hospital-clinic-barcelona-collaborates-with-mediktor-for-improved-patient-assistance-in-tropical-diseases/2024-09-04T12:13:32+02:00https://staging.altals.com/blog/2024/05/27/deepull-appoints-didier-deltort-to-its-board-of-directors/2024-09-04T12:13:06+02:00https://staging.altals.com/blog/2024/05/30/huav-partners-with-mediktor-for-improved-urgent-care-management/2024-09-04T12:12:18+02:00https://staging.altals.com/blog/2024/06/04/mediktor-acquires-sensely-and-consolidates-its-position-as-a-leader-in-ai-healthcare-solutions/2024-06-04T11:37:15+02:00https://staging.altals.com/blog/2024/07/03/todosalud-incorporates-mediktors-ai-into-its-services-as-part-of-its-commitment-to-innovation/2024-09-04T12:09:54+02:00https://staging.altals.com/blog/2024/08/27/peptomyc-s-l-expands-its-patent-portfolio-with-a-patent-grant-in-hong-kong-for-its-methods-and-composition-for-the-treatment-of-cancer/2024-08-27T14:57:55+02:00https://staging.altals.com/blog/2024/09/27/inbrain-neuroelectronics-announces-worlds-first-human-graphene-based-brain-computer-interface-procedure/2024-09-27T10:05:41+02:00https://staging.altals.com/blog/2024/10/30/inbrain-neuroelectronics-raises-50m-series-b-to-advance-graphene-based-brain-computer-interface-technology/2024-10-30T19:10:16+02:00https://staging.altals.com/blog/2024/12/02/deepull-receives-fda-breakthrough-device-designation-for-its-ullcore-bloodstream-infection-test/2024-12-02T16:59:49+02:00https://staging.altals.com/blog/2024/12/09/peptomyc-announces-research-ind-approval-for-innovative-window-of-opportunity-trial-in-collaboration-with-ohsu-knight-cancer-institute-portland-oregon-usa-in-pdac-patients/2024-12-09T13:11:04+02:00https://staging.altals.com/blog/2025/01/16/accure-therapeutics-partner-oculis-reached-positive-phase-2-results-for-lead-neuroprotective-therapy/2025-01-16T10:21:26+02:00https://staging.altals.com/blog/2025/01/16/peptomyc-announces-the-beginning-of-a-phase-2-clinical-trial-of-omo-103-in-advanced-osteosarcoma/2025-01-16T12:31:19+02:00https://staging.altals.com/blog/2025/02/19/ona-therapeutics-strengthens-leadership-team-to-accelerate-first-in-class-adcs-into-clinical-development-across-cancer-types/2025-02-18T20:20:45+02:00https://staging.altals.com/blog/2025/04/07/accure-therapeutics-awarded-a-total-of-1-6m-in-grants-from-the-michael-j-fox-foundation-and-fonds-national-de-recherche-de-luxembourg-to-bring-first-in-class-drug-for-parkinsons-disease-to/2025-04-07T11:04:57+02:00https://staging.altals.com/blog/2025/04/30/deepull-secures-oversubscribed-e50-million-series-c-financing-to-advance-ullcore-diagnostic-system-for-direct-from-blood-rapid-pathogen-detection/2025-04-30T12:22:23+02:00https://staging.altals.com/blog/2025/07/04/peptomyc-announces-leadership-transition-to-support-next-phase-of-growth/2025-07-04T10:10:34+02:00https://staging.altals.com/blog/2025/09/15/inbrain-neuroelectronics-announces-collaboration-to-advance-graphene-based-brain-computer-interfaces/2025-09-15T18:20:30+02:00https://staging.altals.com/blog/2025/09/18/journal-of-medical-economics-study-shows-significant-cost-savings-via-maf-test-guided-adjuvant-bisphosphonate-therapy-for-early-stage-breast-cancer/2025-09-17T12:52:58+02:00